Gerhard C. Hildebrandt
University of Kentucky
Internal medicineOncologyHematologyImmunologyHazard ratioHematopoietic stem cell transplantationLeukemiaMyeloid leukemiaDiseaseGraft-versus-host diseasePopulationTransplantationHematopoietic cellCancer researchMedicineGastroenterology
Publications 205
#1Snigdha Nutalapati (UK: University of Kentucky)
#2Garima Gupta (UK: University of Kentucky)
Last. Gerhard C. Hildebrandt (UK: University of Kentucky)H-Index: 23
view all 3 authors...
Vaccine mediated immune mediated thrombocytopenia (ITP) is exceedingly rare. We present a case of a young female who developed severe refractory ITP with multiple bleeding sites post second dose of COVID-19 vaccination. She was treated with a combination of romiplostim and mycophenolate mofetil that resulted in rapid platelet count recovery.
#2Wang Tao (MCW: Medical College of Wisconsin)
Abstract null null Background null The effect of chronic graft-versus-host disease (cGVHD) on the risk of non-relapse mortality (NRM) and relapse has not been specifically studied in older adults, who are increasingly undergoing allogeneic hematopoietic cell transplantation (alloHCT) and surviving long-term to develop cGVHD. In this Center for International Blood and Marrow Transplant Research analysis, we tested our hypothesis that the risk of NRM was higher with the development of cGVHD, parti...
#1Paul G. Richardson (Harvard University)H-Index: 208
#2Marta Palomo (University of Barcelona)H-Index: 14
Last. Enric Carreras (University of Barcelona)H-Index: 63
view all 6 authors...
Hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), a potentially life-threatening complication of hematopoietic cell transplantation (HCT), results from prolonged sinusoidal endothelial cell activation and profound endothelial cell damage, with sequelae. Defibrotide, the only drug approved in the United States and Europe for treating VOD/SOS post-HCT, has European Commission orphan drug designation for preventing graft-versus-host disease (GvHD), associated with endothelia...
#1Antonio M. Jimenez (UM: University of Miami)H-Index: 9
#2Marcos de Lima (Case Western Reserve University)H-Index: 71
Last. Daniel J. Weisdorf (UMN: University of Minnesota)H-Index: 142
view all 61 authors...
Cytogenetic and molecular abnormalities are known to influence post-transplant outcomes in acute myeloid leukemia (AML) but data assessing the prognostic value of combined genetic models in the HCT setting are limited. We developed an adapted European LeukemiaNet (aELN) risk classification based on available genetic data reported to the Center for International Blood and Marrow Transplant Research, to predict post-transplant outcomes in 2289 adult AML patients transplanted in first remission, be...
#1Kamal Menghrajani (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 6
#2Alexandra Gomez-Arteaga (Cornell University)H-Index: 3
Last. Ulrike BacherH-Index: 53
view all 56 authors...
Little is known about whether risk classification at diagnosis predicts post-hematopoietic cell transplantation (HCT) outcomes for acute myeloid leukemia (AML) patients. We evaluated 8709 AML patients from the CIBMTR database and, after selection and manual curation of cytogenetics data, 3779 patients in CR1 were included in the final analysis: 2384 with intermediate-risk, 969 with adverse-risk, and 426 with KMT2A-rearranged disease. An adjusted multivariable analysis compared to intermediate-ri...
#1Matthew J Wieduwilt (OU: University of Oklahoma)H-Index: 2
#2Leland Metheny (University Hospitals of Cleveland)H-Index: 9
Last. David A. Rizzieri (Duke University)H-Index: 66
view all 77 authors...
The role of haploidentical hematopoietic cell transplantation (HCT) using post-transplant cyclophosphamide (PTCy) for acute lymphoblastic leukemia (ALL) is being defined. We performed a retrospective, multivariate analysis comparing outcomes of HCT approaches by donor for adults with ALL in remission. The primary objective was to compare overall survival (OS) between haploidentical HCT using PTCy and HLA-matched sibling donor (MSD), 8/8 HLA-matched unrelated donor (MUD) , 7/8 HLA-matched UD, or ...
#3Aric C. Hall (UWHC: University of Wisconsin Hospital and Clinics)H-Index: 6
Abstract null null Patients who develop therapy-related myeloid neoplasm, either myelodysplastic syndrome (t-MDS) or acute myeloid leukemia (t-AML) have a poor prognosis. An earlier CIBMTR analysis of allogeneic hematopoietic cell therapy (allo-HCT) (n=868, 1990-2004) showed 5-year overall survival (OS) and disease-free survival (DFS) of 22% and 21%. null Modern supportive care, graft versus host disease (GVHD) prophylaxis and reduced intensity conditioning (RIC) regimens have improved outcomes....
Abstract null Reduced-intensity conditioning (RIC) regimens developed to extend allogeneic stem cell transplantation (HSCT) to older patients have resulted in encouraging outcomes. We aimed to compare the two most commonly used RIC regimens, intravenous use of fludarabine with busulfan (FluBu) and fludarabine with melphalan (FluMel), in myelodysplastic syndrome (MDS). null Through CIBMTR, we identified 1045 MDS patients aged ≥ 60 years who underwent first HSCT with a matched related or matched (...
Vaccine mediated immune mediated thrombocytopenia (ITP) is an exceedingly rare. We present a 25-year-old female who developed severe refractory ITP with multiple active bleeding sites post second dose of COVID vaccination. She was treated with a combination of Romiplostim and Mycophenolate mofetil that resulted in rapid platelet count recovery.
#1Michael Scordo (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 17
#2Trent P Wang (UM: University of Miami)H-Index: 5
Last. Bhagirathbhai Dholaria (VUMC: Vanderbilt University Medical Center)H-Index: 11
view all 39 authors...
Importance Primary central nervous system lymphoma (PCNSL) requires induction and consolidation to achieve potential cure. High-dose therapy and autologous hematopoietic cell transplant (AHCT) is an accepted and effective consolidation strategy for PCNSL, but no consensus exists on the optimal conditioning regimens. Objective To assess the outcomes in patients with PCNSL undergoing AHCT with the 3 most commonly used conditioning regimens: thiotepa/busulfan/cyclophosphamide (TBC), thiotepa/carmus...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.